Cargando…
Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients
FATE and TPTE genes were originally reported to be specifically expressed in the adult testis. We searched for the databases of Unigene and serial analysis of gene expression (SAGE) implying that these two gene transcripts might also be expressed in tumours. Herein, we demonstrated that FATE and TPT...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394243/ https://www.ncbi.nlm.nih.gov/pubmed/12865919 http://dx.doi.org/10.1038/sj.bjc.6601062 |
_version_ | 1782155372269666304 |
---|---|
author | Dong, X-Y Su, Y-R Qian, X-P Yang, X-A Pang, X-W Wu, H-Y Chen, W-F |
author_facet | Dong, X-Y Su, Y-R Qian, X-P Yang, X-A Pang, X-W Wu, H-Y Chen, W-F |
author_sort | Dong, X-Y |
collection | PubMed |
description | FATE and TPTE genes were originally reported to be specifically expressed in the adult testis. We searched for the databases of Unigene and serial analysis of gene expression (SAGE) implying that these two gene transcripts might also be expressed in tumours. Herein, we demonstrated that FATE and TPTE mRNA transcripts were expressed in different histological types of tumours and normal testis. Both are cancer-testis (CT) antigens and renamed as FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, respectively. Comparison at nucleotide sequence, the FATE/BJ-HCC-2 cDNA, was identical to that of FATE, whereas the TPTE/BJ-HCC-5 was found to have two isoforms in both cancers and testis: one was identical in cDNA sequence to TPTE, encoding a protein of 551 amino acids, and the other variant lacked an exon of 54 bp, encoding a protein of 533 amino acids. The mRNA expression was analysed by RT–PCR and real-time PCR. FATE/BJ-HCC-2 mRNA was detected in 66% (41 out of 62) in hepatocellular carcinoma (HCC) samples and 21% (three out of 14) in colon cancer samples, whereas the TPTE/BJ-HCC-5 mRNA was detected in 39% (24 out of 62) and 36% (five out of 14) in HCC and non-small lung cancer samples, respectively. The recombinant proteins were prepared and the reactivity of allogenic sera to these two antigens was screened. The frequency of antibody response against FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 proteins was 7.3% (three out of 41) and 25.0% (six out of 24), respectively, in HCC patients bearing respective gene transcripts. Therefore, FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 are the novel CT antigens capable of eliciting antibody response in cancer patients. |
format | Text |
id | pubmed-2394243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23942432009-09-10 Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients Dong, X-Y Su, Y-R Qian, X-P Yang, X-A Pang, X-W Wu, H-Y Chen, W-F Br J Cancer Molecular and Cellular Pathology FATE and TPTE genes were originally reported to be specifically expressed in the adult testis. We searched for the databases of Unigene and serial analysis of gene expression (SAGE) implying that these two gene transcripts might also be expressed in tumours. Herein, we demonstrated that FATE and TPTE mRNA transcripts were expressed in different histological types of tumours and normal testis. Both are cancer-testis (CT) antigens and renamed as FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, respectively. Comparison at nucleotide sequence, the FATE/BJ-HCC-2 cDNA, was identical to that of FATE, whereas the TPTE/BJ-HCC-5 was found to have two isoforms in both cancers and testis: one was identical in cDNA sequence to TPTE, encoding a protein of 551 amino acids, and the other variant lacked an exon of 54 bp, encoding a protein of 533 amino acids. The mRNA expression was analysed by RT–PCR and real-time PCR. FATE/BJ-HCC-2 mRNA was detected in 66% (41 out of 62) in hepatocellular carcinoma (HCC) samples and 21% (three out of 14) in colon cancer samples, whereas the TPTE/BJ-HCC-5 mRNA was detected in 39% (24 out of 62) and 36% (five out of 14) in HCC and non-small lung cancer samples, respectively. The recombinant proteins were prepared and the reactivity of allogenic sera to these two antigens was screened. The frequency of antibody response against FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 proteins was 7.3% (three out of 41) and 25.0% (six out of 24), respectively, in HCC patients bearing respective gene transcripts. Therefore, FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 are the novel CT antigens capable of eliciting antibody response in cancer patients. Nature Publishing Group 2003-07-21 2003-07-15 /pmc/articles/PMC2394243/ /pubmed/12865919 http://dx.doi.org/10.1038/sj.bjc.6601062 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular and Cellular Pathology Dong, X-Y Su, Y-R Qian, X-P Yang, X-A Pang, X-W Wu, H-Y Chen, W-F Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title_full | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title_fullStr | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title_full_unstemmed | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title_short | Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
title_sort | identification of two novel ct antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients |
topic | Molecular and Cellular Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394243/ https://www.ncbi.nlm.nih.gov/pubmed/12865919 http://dx.doi.org/10.1038/sj.bjc.6601062 |
work_keys_str_mv | AT dongxy identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT suyr identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT qianxp identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT yangxa identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT pangxw identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT wuhy identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients AT chenwf identificationoftwonovelctantigensandtheircapacitytoelicitantibodyresponseinhepatocellularcarcinomapatients |